Understanding how a widely prescribed diabetes and obesity drug protects the heart and kidneys — and whether that protection comes from its novel GIP component or its GLP-1 component — has become one of the most consequential questions in cardiometabolic medicine. A narrative review published in Diabetes, Obesity & Metabolism now attempts to untangle these overlapping mechanisms, with implications for how clinicians should think about tirzepatide relative to older GLP-1-only agents.
The review synthesizes preclinical physiology of glucose-dependent insulinotropic polypeptide (GIP) across cardiac, vascular, renal, and adipose tissue, then anchors the discussion in two landmark clinical programs. In the SURPASS-CVOT trial — the largest cardiovascular outcomes trial for tirzepatide — the drug demonstrated non-inferiority to dulaglutide (a pure GLP-1 receptor agonist) on the three-point major adverse cardiovascular events composite in people with type 2 diabetes and established atherosclerotic disease, while also measurably slowing the decline of estimated glomerular filtration rate in a high-risk chronic kidney disease subgroup. The SUMMIT trial, focused on obesity plus heart failure with preserved ejection fraction (HFpEF), found tirzepatide reduced a composite endpoint of cardiovascular death or worsening heart failure events independent of baseline kidney function — a notably vulnerable population.
What this review cannot yet resolve is arguably more important than what it confirms. The preclinical data on direct GIP receptor activation in cardiac and renal tissue remains genuinely contested — receptors are expressed in these organs, but whether agonism is beneficial, neutral, or context-dependent is unresolved. Because tirzepatide is always a dual agonist in clinical use, it is currently impossible to attribute any observed cardiorenal benefit specifically to the GIP arm versus the GLP-1 arm. The SUMMIT and SURPASS-CVOT trials were not designed to isolate GIP's contribution. This is an important epistemic limitation: the mechanistic story is still being written. For now, tirzepatide's cardiorenal profile appears at least equivalent to — and in some populations potentially superior to — established GLP-1 monotherapy, but the precise molecular authorship of those benefits remains an open and scientifically productive question.